抗人CD19单克隆抗体(克隆号B43) ，体内实验级重组，小鼠IgG2a Kappa | Syd Labs PA007272.m2a
悉得（Syd Labs）体内实验级重组抗人CD19单克隆抗体，小鼠IgG2a Kappa（克隆号B43，货号：PA007272.m2a），纯度>95%，适用于体外和体内研究。其不变区为小鼠Mouse IgG2a Kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
- 产品参数
- 文献
- More Offers
| 货号 | PA007272.m2a |
|---|---|
| 产品名称 | 抗人CD19单克隆抗体(克隆号B43) ，体内实验级重组，小鼠IgG2a Kappa | Syd Labs PA007272.m2a |
| 英文名 | In Vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody（Clone B43）,Mouse IgG2a Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | 悉得（Syd Labs） |
| 别称 | B 淋巴细胞抗原 CD19，分化簇 19，B 淋巴细胞表面抗原 B4，T 细胞表面抗原 Leu-12，CVID3 |
| 概述 | 悉得（Syd Labs）提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | B43 |
| 同种型 | 小鼠 IgG2a Kappa |
| 应用 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人 CD19蛋白影响的生物学途径的测定。 |
| 免疫源 | 抗人 CD19单克隆抗体(克隆号: B43)是用哺乳动物细胞生产的 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD19单克隆抗体(克隆号B43)，小鼠IgG2a Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存3个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007272.m2a 悉得（Syd Labs）提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | 悉得（Syd Labs）在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系悉得（Syd Labs）中国代理商。 关于悉得（Syd Labs）产品如果有任何技术或其它问题，欢迎随时联系悉得（Syd Labs）国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
描述
了解更多抗人CD19单克隆抗体（clone：B43）引用文献，请查看：抗人CD19抗体（克隆号B43）引用文献
抗人CD19单抗（B43）参考文献:
1. CD19 CAR antigen engagement mechanisms and affinity tuning
Changhao He,et al.Sci Immunol. 2023.PMCID: PMC10228544
“Chimeric antigen receptor (CAR) T cell therapy relies on T cells that are guided by synthetic receptors to target and lyse cancer cells. CARs bind to cell surface antigens through a scFv (binder), the affinity of which is central to determining CAR T cell function and therapeutic success. CAR T cells targeting CD19 were the first to achieve dramatic clinical responses in patients with relapsed/refractory B cell malignancies and to be approved by the U.S. Food and Drug Administration (FDA). We report cryo-EM structures of CD19 antigen with the binder FMC63 which is used in four FDA-approved CAR T cell therapies (Kymriah, Yescarta, Tecartus, Breyanzi), and the binder SJ25C1 which has also been used extensively in multiple clinical trials. We use these structures for molecular dynamics simulations which guide creation of lower or higher affinity binders, and ultimately produce CAR T cells endowed with distinct tumor recognition sensitivities. The CAR T cells exhibit different antigen density requirements to trigger cytolysis and differ in their propensity to prompt trogocytosis upon contacting tumor cells. Our work shows how structural information can be applied to tune CAR T cell performance to specific target antigen densities.”
2. A high throughput bispecific antibody discovery pipeline
Aude I. Segaliny,et al.Commun Biol. 2023.PMCID: PMC10082157
“Bispecific antibodies (BsAbs) represent an emerging class of immunotherapy, but inefficiency in the current discovery has limited their broad clinical availability. Here we report a high throughput, agnostic, single-cell-based functional screening pipeline, comprising molecular and cell engineering for efficient generation of BsAb library cells, followed by functional interrogation at the single-cell level to identify and sort positive clones and downstream sequence identification and functionality characterization. Using a CD19xCD3 bispecific T cell engager (BiTE) as a model, we demonstrate that our single-cell platform possesses a high throughput screening efficiency of up to one and a half million variant library cells per run and can isolate rare functional clones at a low abundance of 0.008%. Using a complex CD19xCD3 BiTE-expressing cell library with approximately 22,300 unique variants comprising combinatorially varied scFvs, connecting linkers and VL/VH orientations, we have identified 98 unique clones, including extremely rare ones (~ 0.001% abundance). We also discovered BiTEs that exhibit novel properties and insights to design variable preferences for functionality. We expect our single-cell platform to not only increase the discovery efficiency of new immunotherapeutics, but also enable identifying generalizable design principles based on an in-depth understanding of the inter-relationships between sequence, structure, and function.”
3. A high throughput bispecific antibody discovery pipeline
Aude I. Segaliny,et al.Commun Biol. 2023.PMCID: PMC10082157
“Bispecific antibodies (BsAbs) represent an emerging class of immunotherapy, but inefficiency in the current discovery has limited their broad clinical availability. Here we report a high throughput, agnostic, single-cell-based functional screening pipeline, comprising molecular and cell engineering for efficient generation of BsAb library cells, followed by functional interrogation at the single-cell level to identify and sort positive clones and downstream sequence identification and functionality characterization. Using a CD19xCD3 bispecific T cell engager (BiTE) as a model, we demonstrate that our single-cell platform possesses a high throughput screening efficiency of up to one and a half million variant library cells per run and can isolate rare functional clones at a low abundance of 0.008%. Using a complex CD19xCD3 BiTE-expressing cell library with approximately 22,300 unique variants comprising combinatorially varied scFvs, connecting linkers and VL/VH orientations, we have identified 98 unique clones, including extremely rare ones (~ 0.001% abundance). We also discovered BiTEs that exhibit novel properties and insights to design variable preferences for functionality. We expect our single-cell platform to not only increase the discovery efficiency of new immunotherapeutics, but also enable identifying generalizable design principles based on an in-depth understanding of the inter-relationships between sequence, structure, and function.”
Syd Labs抗人CD19单克隆抗体(克隆号B43)，小鼠IgG2a Kappa （货号：PA007272.m2a）推荐同型对照抗体:
重组小鼠IgG2a同型对照抗体，体内实验级（In Vivo Grade Recombinant Mouse IgG2a Isotype Control Antibody）
Syd Labs提供以下体内实验级重组抗人CD19抗体:
抗人CD19单克隆抗体(克隆号: SJ25c1)（Anti-human CD19 monoclonal antibody (Clone: SJ25C1)）
抗人CD19单克隆抗体(克隆号: B43)（Anti-human CD19 monoclonal antibody (Clone: B43)）
抗人CD19单克隆抗体(克隆号: FMC63)（Anti-human CD19 monoclonal antibody (Clone: FMC63)）
Syd Labs提供以下体内实验级重组抗小鼠CD19抗体:
抗小鼠 CD19单克隆抗体(克隆号: 1D3)（Anti-mouse CD19 monoclonal antibody (Clone: 1D3)）
Syd Labs提供以下流式细胞术用重组抗人CD19抗体:
Syd Labs提供以下流式细胞术用重组抗小鼠CD19抗体:
流式细胞术用抗小鼠 CD19单克隆抗体(克隆号: 1D3)（Anti-mouse CD19 monoclonal antibody (Clone: 1D3) for flow cytometry）
请记住我们的产品信息: 体内实验级重组抗人CD19单克隆抗体(克隆号B43)，小鼠IgG2a Kappa: PA007272.m2a Syd Labs In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa。